This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

Camtek Ltd (NASDAQ:CAMT) reported its financial results for the fourth quarter of 2024, surpassing analyst expectations with an earnings per share (EPS) of $0.77, compared to the forecasted $0.71.